{
    "clinical_study": {
        "@rank": "3152", 
        "acronym": "APOLO-II", 
        "arm_group": {
            "arm_group_label": "Intervention", 
            "arm_group_type": "Experimental", 
            "description": "Intervention"
        }, 
        "brief_summary": {
            "textblock": "The current study is a prospective, single-arm, non-randomized, multi-center study to\n      evaluate the outcome of the ENABLER-P Catheter System for crossing chronic total occlusions\n      during endovascular intervention for femoral-popliteal occlusive disease."
        }, 
        "brief_title": "Accessing Peripheral Occluded LesiOns II (APOLO-II)", 
        "condition": "Femoropopliteal Occlusive Disease", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documentation from a previous attempt OR a concurrent reasonable attempt (at least 5\n             minutes) during this procedure, demonstrating resistance to conventional guidewire\n             crossing;\n\n          -  Patient must have objective evidence of lower extremity ischemia;\n\n          -  Totally occlusive lesion in a native femoropopliteal artery classified\n             angiographically as absolute (100% occlusion with no flow), where no antegrade\n             filling beyond the occlusion is visible;\n\n          -  Target occlusion length is >1cm and  \u2264 30 cm;\n\n          -  Patient's reference vessel diameter is \u2265 4.0 mm and \u22646.0 mm (by visual angiographic\n             estimation)\n\n          -  Patient must be an acceptable candidate for PTA, peripheral artery bypass surgery or\n             peripheral artery stent implantation;\n\n          -  Female patients of child bearing potential must have a negative pregnancy test within\n             48 hours prior to the study procedure;\n\n          -  Patient must have been informed of the nature of the study, agree to its provisions,\n             and provide written informed consent;\n\n          -  Patient is \u2265 21 years of age.\n\n        Exclusion Criteria:\n\n          -  Patient has hypersensitivity or contraindication to aspirin, heparin, Plavix or\n             radiographic contrast agents which cannot be adequately pre-medicated;\n\n          -  The patient requires immediate treatment in more than one occluded vessel, in any\n             combination of grafts or native vessels;\n\n          -  Patient has planned femoropopliteal intervention scheduled within 30 days after index\n             procedure;\n\n          -  The patient is currently participating in another investigational drug or device\n             trial that may conflict with study data collection and has not completed the entire\n             follow-up period;\n\n          -  Patient has no collateral flow distal to the occlusion;\n\n          -  Patient's target occlusion has a dissection that occurred within the past 30 days\n             caused by a guidewire attempt;\n\n          -  Patient has a history of bleeding diatheses, coagulopathy or will refuse blood\n             transfusion in cases of emergency;\n\n          -  Patient suffered recent (within the past 6 months) significant gastrointestinal (GI)\n             bleeding;\n\n          -  Patient's target lesion or the vessel proximal to the target lesion reveals\n             significant ectasia, dissection, aneurysm or thrombus;\n\n          -  Patient has other medical illnesses (i.e., cancer or congestive heart failure) that\n             may cause the patient to be non-compliant with the protocol, confound the data\n             interpretation or is associated with life-expectancy less than 1 year."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "89", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01884701", 
            "org_study_id": "IVO-031"
        }, 
        "intervention": {
            "arm_group_label": "Intervention", 
            "intervention_name": "ENABLER-P Catheter System", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Chronic Total Occlusion CTO", 
        "lastchanged_date": "June 21, 2013", 
        "location": {
            "contact": {
                "email": "thomas.zeller@herzzentrum.de", 
                "last_name": "Thomas Zeller, M.D.", 
                "phone": "004976334022430"
            }, 
            "facility": {
                "address": {
                    "city": "Bad Krozingen", 
                    "country": "Germany", 
                    "zip": "79219"
                }, 
                "name": "Herz-Zentrum"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Accessing Peripheral Occluded LesiOns II (APOLO-II)", 
        "overall_contact": {
            "email": "drydenp@promedic.cc", 
            "last_name": "Paul Dryden", 
            "phone": "+239-498-2155"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "The primary safety endpoint of this study is to evaluate in hospital and 30 day major adverse events (\"MAEs\"), clinically significant perforations, clinically significant embolization and/or Grade C or greater dissections.", 
                "safety_issue": "Yes", 
                "time_frame": "30 days (+/-7 days)"
            }, 
            {
                "measure": "Advancement of the ENABLER-P supported guidewire into or through the CTO in native femoropopliteal artery and subsequent achievement of distal vessel guidewire position with any conventional guidewire.", 
                "safety_issue": "No", 
                "time_frame": "30 days (+/-7 days)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01884701"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "EndoCross Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "EndoCross Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}